Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 13

1.

β-Elemene: Mechanistic Studies on Cancer Cell Interaction and Its Chemosensitization Effect.

Jiang Z, Jacob JA, Loganathachetti DS, Nainangu P, Chen B.

Front Pharmacol. 2017 Mar 9;8:105. doi: 10.3389/fphar.2017.00105. eCollection 2017 Mar 9. Review.

2.

Characterization of Potent SMAC Mimetics that Sensitize Cancer Cells to TNF Family-Induced Apoptosis.

Welsh K, Milutinovic S, Ardecky RJ, Gonzalez-Lopez M, Ganji SR, Teriete P, Finlay D, Riedl S, Matsuzawa S, Pinilla C, Houghten R, Vuori K, Reed JC, Cosford ND.

PLoS One. 2016 Sep 12;11(9):e0161952. doi: 10.1371/journal.pone.0161952. eCollection 2016 Sep 12.

3.

miR-22 and miR-29a Are Members of the Androgen Receptor Cistrome Modulating LAMC1 and Mcl-1 in Prostate Cancer.

Pasqualini L, Bu H, Puhr M, Narisu N, Rainer J, Schlick B, Schäfer G, Angelova M, Trajanoski Z, Börno ST, Schweiger MR, Fuchsberger C, Klocker H.

Mol Endocrinol. 2015 Jul;29(7):1037-54. doi: 10.1210/me.2014-1358. Epub 2015 Jun 8.

4.

Surviving apoptosis: life-death signaling in single cells.

Flusberg DA, Sorger PK.

Trends Cell Biol. 2015 Aug;25(8):446-58. doi: 10.1016/j.tcb.2015.03.003. Epub 2015 Apr 25. Review.

5.

Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy.

Dai X, Zhang J, Arfuso F, Chinnathambi A, Zayed ME, Alharbi SA, Kumar AP, Ahn KS, Sethi G.

Exp Biol Med (Maywood). 2015 Jun;240(6):760-73. doi: 10.1177/1535370215579167. Epub 2015 Apr 7. Review.

6.

Modeling dynamics of cell-to-cell variability in TRAIL-induced apoptosis explains fractional killing and predicts reversible resistance.

Bertaux F, Stoma S, Drasdo D, Batt G.

PLoS Comput Biol. 2014 Oct 23;10(10):e1003893. doi: 10.1371/journal.pcbi.1003893. eCollection 2014 Oct 23.

7.

Cells surviving fractional killing by TRAIL exhibit transient but sustainable resistance and inflammatory phenotypes.

Flusberg DA, Roux J, Spencer SL, Sorger PK.

Mol Biol Cell. 2013 Jul;24(14):2186-200. doi: 10.1091/mbc.E12-10-0737. Epub 2013 May 22.

8.

Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family.

Azijli K, Weyhenmeyer B, Peters GJ, de Jong S, Kruyt FA.

Cell Death Differ. 2013 Jul;20(7):858-68. doi: 10.1038/cdd.2013.28. Epub 2013 Apr 12. Review.

9.

The PI3 kinase inhibitor NVP-BKM120 induces GSK3/FBXW7-dependent Mcl-1 degradation, contributing to induction of apoptosis and enhancement of TRAIL-induced apoptosis.

Ren H, Zhao L, Li Y, Yue P, Deng X, Owonikoko TK, Chen M, Khuri FR, Sun SY.

Cancer Lett. 2013 Sep 28;338(2):229-38. doi: 10.1016/j.canlet.2013.03.032. Epub 2013 Apr 2.

10.

The downregulation of Mcl-1 via USP9X inhibition sensitizes solid tumors to Bcl-xl inhibition.

Peddaboina C, Jupiter D, Fletcher S, Yap JL, Rai A, Tobin RP, Jiang W, Rascoe P, Rogers MK, Smythe WR, Cao X.

BMC Cancer. 2012 Nov 21;12:541. doi: 10.1186/1471-2407-12-541.

11.

Antiapoptotic signaling via MCL1 confers resistance to caspase-3-mediated apoptotic cell death in the pregnant human uterine myocyte.

Stephenson-Famy A, Marks J, Suresh A, Caritis SN, Simhan H, Jeyasuria P, Condon JC.

Mol Endocrinol. 2012 Feb;26(2):320-30. doi: 10.1210/me.2011-1282. Epub 2011 Dec 22.

12.

Quercetin-mediated Mcl-1 and survivin downregulation restores TRAIL-induced apoptosis in non-Hodgkin's lymphoma B cells.

Jacquemin G, Granci V, Gallouet AS, Lalaoui N, Morlé A, Iessi E, Morizot A, Garrido C, Guillaudeux T, Micheau O.

Haematologica. 2012 Jan;97(1):38-46. doi: 10.3324/haematol.2011.046466. Epub 2011 Sep 20.

13.

SB202190-induced cell type-specific vacuole formation and defective autophagy do not depend on p38 MAP kinase inhibition.

Menon MB, Kotlyarov A, Gaestel M.

PLoS One. 2011;6(8):e23054. doi: 10.1371/journal.pone.0023054. Epub 2011 Aug 10.

Supplemental Content

Support Center